Navigation Links
EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting

nical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist(TM)) approved in 32 countries and marketed in Europe. EPIX has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.

This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the progress, timing and results of our clinical development program for PRX-00023 and other drug candidates. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates, including PRX-00023, may fail in the clinic or may not be successfully marketed or manufactured; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials, any failure to comply with regulations relating to our products and product candidates, including FDA requirements; failure to obtain the financial resources to complete development of product candidates; the risk that the FDA may interpret the results of our studies differently than we have; competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; the possibility of delays in the research and development necessary to select drug
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/28/2015)...  Today, in final recognition of the Centers for ... 1-800 Contacts is sharing how to keep lens cases ... who do not properly care for their lens cases ... Most contact lens wearers understand the importance ... case is sometimes overlooked.  When proper steps to clean ...
(Date:8/28/2015)... Ill. , Aug. 28, 2015 ... Companies, Inc. (Nasdaq: PDCO ), is now ... previously announced acquisition of Patterson Medical by Madison ... will retain its name for a transition period ... of rehabilitation and sports medicine products.  With the ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by AstraZeneca ... is an important drug for the treatment of ... 2000, quetiapine was listed in the Catalogue of ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Quetiapine Market Investigation Report 2010-2019 2
... Quantum Materials Corporation ( ... QTMM ) Quantum Materials Corp. and Nanoaxis, LLC ... tetrapod quantum dot mass production technology with Nanoaxis advanced research ... aim of the alliance is to develop Tetrapod Quantum Dot ...
... Sharp HealthCare,s affiliated medical groups -- Sharp Rees-Stealy ... Status, the highest possible designation for quality care given ... part of its 2011 Standards of Excellence program. CAPG ... managed care physician groups. "We are grateful ...
Cached Medicine Technology:Quantum Materials Corp and Nanoaxis Announce Technology Alliance 2Quantum Materials Corp and Nanoaxis Announce Technology Alliance 3Sharp HealthCare Medical Groups Recognized for "Elite" Care 2Sharp HealthCare Medical Groups Recognized for "Elite" Care 3
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
(Date:8/28/2015)... ... 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. , ... Illinois, and then went on to earn his title of Doctor of Chiropractic from ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery is ... and only nonsurgical product approved by the Food and Drug Administration to eliminate submental ... Dr. William Koenig are among the premier cosmetic surgeons in Rochester to ...
(Date:8/28/2015)... ... , ... Mendon, IL, home of the Adams County Fairgrounds, was treated once ... good cause. In its second year, the “Music With A Mission” benefit concert was ... “Mission” of “Music With A Mission” is to raise money to help fund music ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... , THURSDAY, Sept. 29 (HealthDay News) -- One-quarter of American ... to new research from the U.S. Agency for Healthcare Research ... blood pressure, also known as hypertension, 29 percent were black ... federal agency noted in its Sept. 27 News and ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Campus-wide smoking bans ... habit, new research suggests. The finding stems from a ... a ban and one without. "Although we haven,t pinpointed ... most to the positive changes in students, smoking rates, having ...
... DCThrough the identification of a gene,s impact on a ... continue to make progress in understanding the mechanics ... of white matter, known as myelination. The study, published ... of The Journal of Neuroscience , identified Sox17 ...
... might think, cancer and diabetes appear to have some biology in ... the Cell Press journal, Cell, a pathway that initially ... also influences the odds that mice develop or resist diabetes. ... Lin28b become more sensitive to insulin and less prone to diabetes ...
... , HOUSTON, Sept. 29, 2011 Hormone researchers at ... on providing long-term treatment options for diabetes, obesity and ... naturally occurring estrogen. They now believe that ... body functions in both females and males. While estradiol ...
... 28, 2011 - (BRONX, NY) - People taking oral steroids ... severe vitamin D deficiency, according to a study of more ... Albert Einstein College of Medicine of Yeshiva University. Their ... of Clinical Endocrinology and Metabolism, suggest that physicians should more ...
Cached Medicine News:Health News:1 in 4 U.S. Adults Treated for High Blood Pressure: Report 2Health News:Campus Smoking Bans May Help College Students Quit 2Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Diabetes and cancer: A shared biological basis 2Health News:UH researchers explain hormonal role in glucose and fat metabolism 2Health News:Oral steroids linked to severe vitamin D deficiency in nationwide study 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Medicine Products: